Companies /Healthcare

Bioventus Inc - Class A

NASDAQ: BVS Medical Devices
$13.79
▼ $0.18 (−1.29%) today
Markets closed · 8:31pm ET

Q1 2026 Earnings

Reported May 6, 2026, 7:46am ET · SEC source
$0.15
Beat +120.59%
EPS · est. $0.07
$132.1M
Beat +1.69%
Revenue · est. $129.9M
−18.8%
Trailing market
BVS vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−8%−4%0+4%May 6May 7report 7:46am ETearnings−0.1%−0.9%
−8%−4%0+4%May 6May 7earnings−0.1%−0.9%
BVS −0.9%S&P 500 −0.1%
−8%−4%0+4%May 6May 7report 7:46am ETearnings+0.1%−0.9%
−8%−4%0+4%May 6May 7earnings+0.1%−0.9%
BVS −0.9%NASDAQ +0.1%
−8%−4%0May 5May 13report 7:46am ETearnings+1.7%−5.2%
−8%−4%0May 5May 13earnings+1.7%−5.2%
BVS −5.2%S&P 500 +1.7%
−8%−4%0+4%May 5May 13report 7:46am ETearnings+3.3%−5.2%
−8%−4%0+4%May 5May 13earnings+3.3%−5.2%
BVS −5.2%NASDAQ +3.3%
+2.25%
Day of report
−2.47%
Next session
−4.76%
One week
−18.04%
30 days

S&P 500 over the same 30 days: +0.73%.

Did BVS Beat Earnings? Q1 2026 Results

Bioventus Inc. posted a standout first quarter of 2026, with adjusted EPS of $0.15 beating the $0.07 consensus estimate by 120.59% and revenue of $132.09 million edging past the $129.90 million forecast by 1.69%, reflecting 6.6% year-over-year growth. The most material driver of the upside was a broad-based contribution across all three business segments, headlined by a favorable $4.20 million rebate adjustment in Pain Treatments and sustained U.S. demand in Surgical Solutions, where Bone Graft Substitutes and Ultrasonics each gained traction. Profitability improved sharply, with Adjusted EBITDA expanding 24% to $23.91 million and Non-GAAP operating margin widening to 15.4% from 14.3% a year earlier. Notably, operating cash flow swung to $8.93 million from an outflow of $19.33 million in the prior-year period, allowing Bioventus to make a discretionary $22.00 million term loan prepayment in late March. Management responded to the momentum by raising full-year Adjusted EPS guidance to $0.75–$0.79 and Cash from Operations guidance to $84.00–$89.00 million, while reaffirming net sales guidance of $600.00–$610.00 million for 2026.

Key Takeaways
  • Favorable $4.2 million rebate benefit from billing process change by a third-party private insurer in Pain Treatments
  • Higher U.S. demand for Bone Graft Substitutes and Ultrasonics in Surgical Solutions
  • Continued commercial effectiveness and sales force execution with EXOGEN Bone Stimulation System
  • Strong international growth of 17.1% driven by Ultrasonics and HA therapies for knee osteoarthritis
  • Net interest expense declined to $4.3 million from $7.5 million due to debt reduction
  • Non-GAAP gross margin expanded to 76.4% from 75.3%

“Our team delivered a strong start to 2026, driven by continued momentum in our core businesses and disciplined execution across our commercial and operational priorities.”

Bioventus CEO, on the earnings call

Forward Guidance & Outlook

Bioventus raised full-year 2026 guidance for Adjusted EPS to $0.75–$0.79 (up $0.02 from prior guidance) and Cash from Operations to $84 million–$89 million (up $2 million), driven by accelerated cash flow and faster-than-anticipated debt repayment. The company reaffirmed its 2026 net sales guidance of $600 million to $610 million, reflecting approximately 6%–7% growth.

BVS YoY Financials

Q1 2026 vs Q1 2025 · SEC filings Q1 2025 Q1 2026
$0$40.0M$80.0M$120.0M$123.9M$132.1MRevenue$83.1M$90.8MGross Profit$4.9M$8.4MOperating Income$978,777$3.1MNet Income
$0$40.0M$80.0M$120.0MRevenueGross ProfitOperating IncomeNet Income

BVS Revenue by Segment

Pain Treatments$63.4M+7.7%
Surgical Solutions$48.0M+6.2%
Restorative Therapies$20.6M+4.6%

BVS Revenue by Geography

United States$116.4M+5.4%
Rest of World$15.6M+17.1%

Figures from SEC filings and company reports. Not investment advice.